Jeddah: Takeda, the R&D-driven global biopharmaceutical company, and the Saudi Gastroenterology Association (SGA), have signed a new partnership agreement with the aim to advance inflammatory bowel disease (IBD) care in the Kingdom of Saudi Arabia. The agreement, signed on the sidelines of the annual SGA congress held in Jeddah, will see the two parties work together to raise IBD awareness and advance knowledge and capabilities across Saudi Arabia’s healthcare sector.
It is estimated that…